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Naphthylisoquinoline alkaloid-containing extracts from species of the families Dioncophyllaceae and Ancis­
trocladaceae and purified alkaloids derived therefrom were shown to exhibit antiparasitic activity in Plasmo­
dium berghei-mfucttd. mice. Several extracts and alkaloids, especially dioncophylline C and dioncopeltine A, 
isolated from Triphyophyllum peltatum (Dioncophyllaceae), displayed high levels of activity. Dioncopeltine A was 
able to suppress parasitemia almost totally, while dioncophylline C cured infected mice completely after oral 
treatment with 50 mg kg of body weight-1 day-1 for 4 days without noticeable toxic effects. Analysis of the 
dose-response relationship of dioncophylline C revealed a 50% eifective dosage (EDS0) of 10.71 mg kg-1 day-1 
under these conditions. Although four daily treatments with 50 mg kg-1 day-1 are needed to achieve radi­
cal cure, one oral dose is sufficient to kill 99.6% of the parasites. Intravenous application of dioncophylline 
C is even more effective, with an EDS0 of 1.90 mg kg-1  d ay-1  and no noticeable toxic effects. The compound 
also suppressed more established P. berghei infections when orally applied at day 3 after infection. Both 
dioncopeltine A and dioncophylline C are active against the chioroquine-resistant P. berghei Anka CRS 
parasites. Sustained release of these compounds at 20 mg kg-1 day-1 by implanted miniosmotic pumps 
exhibited curative effects. The naphthylisoquinoline alkaloids are therefore promising new antimalarial 
agents.
•  .  ¿ > .4 .  u *  V»* . . . .  . .  -------------  ^—  t l I • • - I- I I  I I ‘I I  b i - t - . .....................  . . . . . i j ,  L . u J t L  4 * J .  ^  « . < > ♦ '  a .  A. ^  .  JU
More than ever, malaria is one of the most threatening 
tropical diseases and causes inexpressible suffering in more 
than 90 countries. Official estimates range between 1.5 million 
and 2.7 million fatal eases and between 300 million and 500 
million clinical cases of malaria per year, and these are accom­
panied by considerable socioeconomic damage (18, 49). Con­
trol of the disease is, among other factors, hampered by 
resistance of the vector {Anopheles spp.) to insecticides and 
an ongoing spread o f drug-resistant strains of Plasmodium  
falciparum , the malaria parasite most dangerous to humans. 
Resistance to chloroquine has become very common not 
only in Southeast Asia but also in considerable parts of 
Africa, South America, and Oceania. At present, there is no 
country in sub-Saharan Africa from which chloroquine re­
sistance has not been reported (1, 38). Multidrug resistance 
increases in intensity and spreads geographically. In South­
east Asia and, more specifically, in the border regions be­
tween Thailand and both Myanmar (Burma) and Cambodia, 
P. falciparum  has developed resistance to all commonly
available antimalarial drugs (16, 28, 32, 39, 47, 48). In ad­
dition, the emerging resistance o f Plasmodium vivax to a
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t  This is part 9 in the series Antiprotozoal Activity of Naphthyliso- 
quinoline Alkaloids (for Part 8, see reference 26). This is part 97 in 
the series Acetogenic Isoqinnolinc Alkaloids (for part 96, see ref­
erence 14).
variety of drugs has been reported (35, 36, 41). On the basis 
o f  th ese  facts, it is obvious that new antimalarial agents are
urgently  needed (37).
Extracts from species of the families Dioncophyllaceae and 
Ancistrocladaceae (6), tropical lianas containing naphthyliso­
quinoline alkaloids, a new class of natural products with special 
structural and biosynthetic characteristics (3, 5, 10), have been 
w idely applied in traditional medicine of several African and 
A sian  countries. Dioncophyllum thollonii (Dioncophyllaceae) is 
know n for its activity against leprous skin disease (31), Ancis-
trocladus abbreviatus (Ancistrocladaceae) is known for its activ­
ity against measles and fevers (27), and Ancistrocladus tectorius 
is known for its activity against dysentery and malaria (43). 
Several extracts from such species and naphthylisoquinoline 
alkaloids derived therefrom, as well as synthetic mono- and 
dim eric alkaloids, exhibit a variety of biological activities (10). 
T h ey  are especially active against asexual erythrocytic stages
o f  P. falciparum  NF 54 and K.1 and Plasmodium berghei 
A n k a  in vitro (2, 11-13, 20-23, 25, 26). These intracellular 
stages are of particular interest, being responsible for all 
clinical malaria symptoms (46). Besides, the potential of naph­
thylisoquinoline alkaloids against exocrythrocytic stages of 
P. berghei in human hepatoma cells has recently been demon­
strated (24, 26), These results, combined with the low cytotox­
icity o f  the compounds (23), make them candidates for in vivo 
testing. The availability of a selection of alkaloids permitted 
experim ents on their antimalarial activities in P. berghei-in- 
feeted  rodents (30, 34) as part of the preelinieal phase of their
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TABLE 1. Treatment of P. berghei Anka-infected OF1 mice with extracts from T. peltatum (Dioncophyllaceae)
J  A  ____ _______________/  ______ 7 . .  J , .  „ - w ,
Treatment
Control 
T. peltatum  
R oot (CH2CU)
Stem bark (CH2CI2)
Stem bark (CH2C12-NI-I3)
% Parasitemia*
3.18 (2.82-3.54)
3.78 (3.01-4.54) 
3.05 (2.14-3.97) 
0.80 (0.40-1.19)
and A. abbreviatus (Ancistrodadaceae)  
Day 4
p c
0.099'' 
0.723^ 
< 0 .0 0 0 1 ''
No. of dead mice/ 
total no. of mice
0/6
0/6
0/6
0/6
% Parasitemia
4.30 (0.00-8.62) 
6.99
6.52 (0.00-29.32) 
3.85 (1.47-6.22)
Day 7
P
0.349‘/
0.714f/
n n
No. til' dead mice/ 
total no. of mice
4/6
5/6
4/6
A. abbreviatus
R oot (CH,C12-NH3) 
Stem bark (CH2C12-NH3)
3.50 (2.35-4.64) 
3.57 (2.81-4.33)
0.520i7
0.260£/
" Mice were orally treated with 50 mg of extract kg"1 day-1 in a 4-day 
b Values are mean levels of parasitemia (95% confidence intervals). 
r Probability level of difference with control values. 
d Not significantly different from controls in one-way ANOVA. 
e Significantly different from controls in one-way ANOVA.
0/6
0/6
5.35 (0.00-14.43) 
7.72 (0.00-17.38)
0 .318
a u m
4/6
W W H M H W
MATERIALS AND METHODS
«
Extracts. Specimens óf Triphyophyllum peltatum and A. abbreviatus were col­
lected by L. Aké Assi in western Ivory Coast in January 1988 and July 1990, 
respectively. Voucher specimens were deposited at the Conservatoire et Jardin 
Botaniques de TUniversitê d’Abidjan, Abidjan, Ivory Coast. The air-dried, 
ground root and stem bark material was first lyophilized and was subsequently 
extracted in a Soxhlet apparatus by consecutively using CH2C12 and CH2Cl2-NH3 
(98:2) as eluents. The solvents were removed under reduced pressure.
Naphthylisoquinoline alkaloids. The following naturally occurring alkaloids 
(see Fig. 1) were isolated from T. peltatum and were characterized as described 
before: dioncophyllines A (compound 1) (4), B (compound 2) (7), and C (com­
pound 3) (9) and dioncopeltine A (compound 4) (8).
P . berghei strains. P. berghei Anka and K173 (15, 29, 33) erythrocytic stages 
were obtained from cryopreserved samples kept at the Prins Leopold Instituut 
voor Tropische Geneeskunde, Antwerp, Belgium, and the Sint Radboud Zie­
kenhuis, Nijmegen, The Netherlands, respectively. The chronic ehloroquine- 
resistant CRS line was derived from the Anka strain by serial passages in Wistar 
rats and OF1 mice (44, 45).
Laboratory animals and drug administration. Six-week-old, outbred female 
OF1 mice were purchased from Iffa Credo, Brussels, Belgium. Drugs were orally 
administered with the aid of a stainless steel probe (0.8 by 3.2 cm) directly 
introduced into the esophagus. In part of the experiments, drugs were injected 
subcutaneously in the neck region or intravenously in one of the lateral tail veins. 
Six-week-old, inbred female C57Black/6J and outbred male and female Swiss
*
mice were obtained from local colonies of the Central Animal Facility of the 
Katholieke Universiteit Nijmegen and were raised and kept under specific- 
pathogen-free conditions. The C57Black/6J mice were used in the experiments 
with implanted osmotic pumps. All mice were housed and handled in conformity 
with national and international legislation and guidelines, Drinking water and 
food were available ad libitum.
Antimalarial activity in vivo. The antimalarial activities of extracts and alka­
loids were determined by a standard 4-day test (40, 42) applied to P, berghei- 
infected mice.
The OF1 mice were divided into groups of six mice each. At day 0, they were 
infected intraperitoneally with 10° erythrocytic forms of P. berghei Anka obtained 
from a heavily infected donor mouse. Two hours later, all but the control mice 
received an oral dose varying from 3.125 to 100 mg of extract kg of body weight 1 
or pure naphthylisoquinoline alkaloid dissolved in a minimal volume of dimethyl 
sulfoxide (DMSO) adjusted to 0.2 ml with saline. The controls received 0.2 ml of 
the same concentration of DMSO in saiine. The treatment was given daily for 4 
consecutive days (days 0 to 3). At days 4 and 7, thin smears of tail blood were 
made, fixed with methanol, and stained with Giemsa. The level of parasitemia 
(percentage of infected erythrocytes) was determined microscopically (magnifi­
cation, x  1,000; Leitz) by examination of 10,000 cells. In modified regimens, the 
drugs were administered starting at different days after the infection for various 
periods of time and by different routes.
Sustained release by mini-osmotic pumps. Mini-osmotic pumps with a How 
rate of 1 (xl/h (Alxet, type 2001; Charles River Deutschland GmbH, Kislegg, 
Germany) were filled with dioncophylline C and dioncopeltine A, dissolved in a 
minimal amount of DMSO, and diluted with physiological saline to obtain a 
concentration of 16.6 mg/ml, providing a sustained release of 20 mg kg 1 day \  
Those prepared for the control group contained the same concentration of 
DMSO in saline.
The pumps were implanted subcutaneously in the backs of C57Black/6J mice 
at day -1 ,  and all mice were inoculated intraperitoneally with 10ft P. bettfhei K173 
parasites at day 0. The level of parasitemia was determined as described above. 
The »surviving mice were sacrificed at day 28 after infection.
The absence of circulating parasites in treated, smear-negative C57Blaek/(U 
mice was verified at day 14 after infection by the transfer of 0.1 ml of blood into 
naive Swiss mice that were examined for the development of parasitemia for a 
4-week period.
Treatment
Control
Dioncophylline A 
Dioncophylline B 
Dioncophylline C
Dioncopeltine A
TABLE 2. Treatment of P; bei*ghei Anka-infected OF1 mice with m
from T. peltatum. (.Dioncophyllaceae)*1
Day 4
% Parasitemia ƒ*■ No. of dead mice/ total no. of mice
3.50 (3.02-3.97) 
2.96 (2.61-3.30) 
1.86 (0.66-3.07) 
0.00 (0.00- 0.00) 
0.03 (0.01-0.06)
0.1271 
0.009e
<o.ooor
co.ooor
0/6
0/6
0/6
0/6
0/6
" Mice were orally treated with 50 mg of alkaloid kg-1 day"1 in a 4-day 
h Values are mean levels of parasitemia (95% confidence intervals).
*' Probability level of difference with control values. 
r/ Not significantly different from controls in one-way ANOVA. 
Significantly different from controls in one-way ANOVA.
% Parasitemia
8.70 (0.00-45.80) 
8.97 (8.09-9.85) 
8.49 (2.70-14.29) 
0 .0 0
2.21 (1.35-3.06)
alkaloids
Day 7
P
Q.95T*
0.959*'
0 .0 0  V
0.005''
a m
No. of dead miec/ 
total no. of mice
moatf
4/6
3/6
1/6
0/6
M a
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h3c o
Dioncophylline A (1)
o c h 3
Dioncophylline B (2)
HO OCH3
h3c o
Dioncophylline C (3) Dioncopeltine A (4)
FIG. I. Structures of the naphthylisoquinoline alkaloids (compounds 1 to 4).
Analysis of the results. Statgraphics (Graphic Software Systems) was used for 
statistical analysis of treatment versus control data (one-way analysis of variance 
|ANOVA]; threshold, P ~  0.050). The sigmoid dose-response curves were lin­
earized by probit transformation (17, 19) for the determination of effective 
dosages (EDs).
RESULTS
P. berghei-infected O Fl mice were orally treated with three 
extracts from T. peltatum  and two extracts from A. abbreviatus 
in the 4-day test (Table 1). The CH2Cl2-NH3 stem bark extract 
from T. peltatum suppressed the parasitemia significantly (day 
4), while the other four extracts were inactive. Several pure 
naphthylisoquinoline alkaloids from T. peltatum  were highly 
active (Table 2). Dioncophylline B and dioneopcltine A sup­
pressed the parasitemia significantly (47 and 99%  at day 4, 
respectively), while dioncophylline C was the most active 
compound tested and completely clcared the parasites from 
the peripheral blood. Dioncophylline A had no effect (Fig. 
! ) •
3
Administration of dioncophylline C at dosages ranging from 
.125 to 100 mg kg 1 day to P. berghei-infected mice by the
4-day test revealed significant inhibitory activities at 12.5 mg 
kg 1 day 1 and higher dosages (Table 3). The calculated EDs
(with their corresponding 95% confidence intervals given in 
parentheses) at day 4 are as follows: 25% ED (ED 25), 6.81 mg 
kg"1 day""1 (5.48 to 8.46 mg kg'"1 day'"'); EDiu, 10.71 mg kg 1 
day” 1, (8.94 to 12.83 mg kg"'1 d a y 1); and E D t,s, 32.44 mg 
kg~1 day“ 1 (23.40 to 44.98 mg kg" 1 day '). The effective range 
for oral application of dioncophylline C is 12,5 to 50 mg kg 1 
day-1 , since dosages below 12.5 mg kg 1 day 1 did not sup­
press proliferation of the parasite and 100 mg kg 1 day 1 
caused a mild but transient neurotoxic effect in one of six
treated mice. The initial reduction of the parasitemia by 
ages of 12.5 and 25 mg kg 1 day 1 up to day 4 was not 
sufficient to prolong the mean survival limes of the animals, in 
contrast to the complete cure caused by 50 and 100 mg kg 1 
day“'1. No obvious acute or chronic side effects could be noted 
in OF1 mice treated with four dosages of 50 mg kg 1 day l. 
They looked normal and behaved absolutely normally during 
several months of observation after the treatment.
Administration of a single dosage of 50 mg of dioncophylline 
C kg 1 day 1 at day 0 suppressed the parasitemia by 99.6% 
until day 4 postinfection, but four daily treatments were re­
quired for complete cure (Table 4). The proportion of mice 
that cleared the parasitemia increased with the number of daily 
applications: none of six, two of six, and five of six mice after 
one, two, and three applications, respectively, indicating a 
strict linear dose-response relationship (r = 0.984) and result­
ing in 2.38 daily treatments to cure 50% of the mice.
Dioncophylline C was also administered via other routes by 
using the 4-day schedule. Both the subcutaneous and intrave­
nous routes were proven to be effective, although the effects 
were not strong enough to persist until day 7. Subcutaneous 
application of 20 mg kg"1 clay '1 reduced the level of para­
sitemia by ca. 84% (P <  0.001) at day 4, while dosages of 5 and 
1.25 mg kg 1 day.1 had no effect. These results are compara­
ble to those obtained after oral administration of dioncophyl­
line C (Table 3). Intravenous injection of the compound was 
more effective, since dosages of 20, 5, and 1.25 mg kg 1 day 1 
suppressed the parasitemia at day 4 by 89% (P <  0,0001), 38%'
( U  —
spending calculated EDs (with their 95%  confidence intervals 
given in parentheses) at day 4 are as follows: E D 25, 0.56 mg 
1 day 1 (0.11 to 2.95 mg kg" 1 day '); EDS0, 1.90 mg kg 1 
1 (0.72 to 5.00 mg kg 1 day ’); and ED,)5, >20 mg kg 1 
It should be noted that even in the case of intravenous
0.007), and 43% (P =  0.006), respectively. The corre
kg 
day 
day
injection of dioncophylline C, no signs of acute or subchronic
were
Administration of dioncophylline C to OFl mice with estah m
'FABLE 3. Correlation between suppression o f parasitemia of P. berghei Anka-infected OFl mice" and applied doses o f dioncophylline ('
Applied dose of 
dioncophylline C 
(mg kg 1 day ‘)
Day 4 D ay 7 Survival time (days) 
Mean*' I*% Parasitemia* r
No. of dead mice/ 
total no. of mice % Parasitemia P
No. of dead mice/ 
total no. of mice
Control 5.66 (3.81-7.51) 0/6 7.72(0.30-15.13) 3/6
'rTTitrrfr 3ip?Vi t a v t '1 r-i- ^ ' ■ i\ i.w>gr •,.> . rv  >: ■ y i j-jv
10.00 (3.99 I(k()|)
•1—
3.125 5.36 (3.96-6.75) 0.748'- 0/6 8.69(7.18-10.19) 0.616'' 3/6 6,17 (5.38 6.96) 0.135’
6.25 4.42 (2.77-6.06) 0.226'' 0/6 9.10(7.44-10.75) 0.261*' 2/6 5,83 (5.04-6.62) 0.1 OK"
12.5 3.36 (2.35-4.37) 0.019' 0/6 7.49 (5.67-9.32) 0.891' 1/6 13.33 (5 .54 -21.1.1) 0.413'
25 0.62 (0.00-1.34) <0.001' 0/6 5.24 (2.66-7.83) 0.224'' 0/6 13,33 (9.90-16.76) 0.244'
50 0.000 (0.000-0.000) <0.0001' 0/6 0.000 (O.OOO-O.OOO) • 0.001' 0/6 >  85 • 0.0001'
100 O.OOO (O.OOO-O.OOO) <0.0001' 0/6 0.000 (0.000-0.000) • 0,0001' 0/6 >  85 • 0.0001'
" Mice were orally treated with dioncophylline C in a 4-day test. 
h Values are mean levels of parasitemia (95% confidence intervals). 
r Probability level of difference with control values.
J Values are mean survival times (c)5% confidence intervals).
*’ Not significantly different from controls in one-way ANOVA.
J Significantly different from controls in one-way ANOVA.
'<•'"1 llliai 11 n w y g g n »  üMtouiTifrir i  v r r t  u
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TABLE 4. Effect of number of treatments of P. berghei-infected O Fl mice with di
No. of treatments with 
dioncophylline C
Day 4
% Parasitemia* p c
Control
Onef/
T W
Three®
FouiJi
5.66 (3.81-7.51) 
0.02 (0.00-0.05) 
0.01 (0.00- 0.02) 
0 .0 0 0  (0 .0 0 0 -0 .0 0 0 ) 
0 .0 0 0  (0 .0 0 0 -0 .0 0 0 )
<o.ooor
< 0.0001£'
co.ooor
< 0.0001£’
" Mice were orally treated with 50 mg of dioncophylline C kg- 1 day 
h Values are mean levels of parasitemia (95% confidence intervals). 
c Probability level of difference with control values. 
d Treatment at day 0.
‘'Significantly different from controls in one-way ANOVA. 
•'Treatments at days 0 and 1. 
s Treatments at days 0, 1, and 2.
'' Treatments at days 0, 1, 2, and 3.
i
No. of dead mice/ 
total no. of mice
0/6 
0/6 
0/6 
0/6 
0/6
% Parasitemia
7.72 (0.30-15.13) 
1.23 (0.35-2.10) 
0.07 (0.00-0.19) 
0.001 (0.000- 0.002) 
0 .0 0 0  (0 .0 0 0 -0 .0 0 0 )
Day 7
P
0.012e 
<0.001e 
< 0.001* 
c o .o o r
No. of dead mice/ 
total no. of mice
3/6
0/6
0/6
0/6
0/6
lished infections (Table 5) revealed that a first oral dosage of DISCUSSION  
50 mg kg-1 day-1 at day 3 after infection was sufficient to
suppress the parasitemia significantly (45.1% inhibition at day Several extracts derived from Dioncophyllaceae and Ancis-
4). Additional dosages at days 4, 5, and 6 each caused further trocladaceae species display strong in vitro activities against
reductions (91.2, 98.4, and 99.7%, respectively), and the last P. falciparum and P. berghei erythrocytic stages (20, 22, 23). To
treatment, at day 7, cured all animals. explore their in vivo potentials, a selection was administered to
Dioncophylline C and dioncopeltine A, the most potent in P. berghei-ivdtcitd O Fl mice in a standard 4-day test (40, 42).
vitro and in vivo naphthylisoquinoline alkaloids identified until 
now (20, 22, 23) (Table 2), were administered orally to O Fl 
mice infected either with chloroquine-sensitive and virulent 
P. berghei Anka parasites or with resistant and chronic P. 
berghei Anka CRS parasites (Table 6). While both compounds 
suppressed the parasitemia considerably at least until day 7 
after infection, in each of the cases, dioncophylline C was more 
active. The suppressive activity was less pronounced against
The highly active T. peltatum  (Dioncophyllaceae) C H 2C12-NH, 
stem bark extract (50% inhibitoiy concentrations [IC50s], 0.014 
and 0.081 (xg/ml for P. falciparum and P. berghei in vitro, 
respectively) strongly suppressed the development o f para­
sitemia in O Fl mice (Table 1), thus supporting the in vitro 
observations.
The IC50s of naphthylisoquinoline alkaloids derived from 
T. peltatum  (dioncophyllines B and C and dioncopeltine A) for
the resistant line (dioncophylline C, 87% at day 4; dioncopel- P. falciparum and P. berghei in vitro were far below 1 (Jig/ml,
tine A, 72% at day 4), and complete cure was not obtained in 
the 4-day regimen.
while the corresponding value for dioncophylline A  was about 
1 jxg/ml in both systems (20, 22, 23). Again, the compounds
Sustained administration of both dioncophylline C and di- with the highest in vitro activities were by far the most effective 
oncopeltine A to C57Black/6J mice was obtained via subcuta- 
neously implanted mini-osmotic pumps (Table 7). A daily dose
ones in vivo, as shown in the cases of dioncophyllines B and C 
and dioncopeltine A (Table 2). The best in vivo results were 
obtained by treatment with dioncophylline C (IC5()s, 0.014 and 
confirmed by isodiagnosis with Swiss mice. Very low levels of 0.015 (xg/ml for blood forms of P. falciparum  and P. berghei in 
parasitemia ( < l % )  were determined in some of the mice at vitro, respectively) of P. berghei-infected OFl mice, causing a
of 20 mg kg 1 resulted in both cases in a rapid and radical cure
days 5 and 6 during the dioncopeltine A treatment but only at 
day 5 during the dioncophylline C treatment.
complete clearance of parasites after oral administration of 50 
mg kg 1 day 1 (Table 2).
Time after 
infection (day)
3
4
5
6
7
8 
10 
13
TABLE 5. Effects of treatment with dioncophylline C' on established parasitemia in OFl mice infected
with 10(l P. berghei. Anka blood forms at day 0
Control
% Parasitemia''
0.78 (0.59-1.00) 
2.26 (1.79-2.73) 
5.11 (1.51-8.70) 
3.67 (1.17-6.17)
2.91 (2.15-3.67) 
3.30 (0.00-10.40) 
25.61 (5.38-45.83) 
38.08
No. of dead mice/ 
total no. of mice
0/6 
0/6 
0/6 
1/6 
3/6 
3/6 
3/6 
5/6
% Parasitemia
0.95 (0.72-1.18) 
1.24(0.80-1.69) 
0.45 (0.24-0.65) 
0.06 (0.02-0.09) 
0.01 (0.00-0.02) 
0.00 (0.00- 0.00) 
0.00 (0.00- 0.00) 
0.00 (0.00- 0.00)
" Mice were orally treated with 50 mg of dioncophylline C kg "1 day 
h Parasitemia levels were determined prior to the next treatment. Vi 
v Probability level of difference with control values.
'' Not significantly different from control in one-way ANOVA. 
''Significantly different from controls in one-way ANOVA.
i ,at days 3, 4, 5, 6, and 7. 
■s are means confidence intervals).
Treatment
/**
0.197 
0.002e 
0.008' 
o.oor  
< 0.0001* 
0 .0 1 8 ' 
<0.00 r  
<0.000 r
n in m n > .......... h iH iU n .m n 'n i '.H W i
No. of dead mie cl 
total no. of mice
m u m  i n u m a w i w  » w rw m
0/6
0/6
0/6
0/6
0/6
0/6
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Sensitive (Anka) 
Control
Dioncophylline C 
Dioncopeltine A
Resistant (Anka CRS) 
Control
Dioncophylline C 
Dioncopeltine A
TABLE
P. berghei strain and 
treatment
JL J  ^  ~  A X  U i  W 1  X  l i a
chloroquine-sensitive and -resistant strains of P. berghei
% Parasitemia*
4.17 (2.40-5.93) 
0 .0 0 0  (0 .0 0 0 -0 .0 0 0 ) 
0.01 (0.00-0.03)
0.79 (0.68-0.90) 
0.10 (0.05-0.15) 
0.22 (0.07-0.36)
Day 4
p c
<0.001d
< 0 . 0 0 1 d
<0.0001d
<0.0001rf
No. of dead mice/ 
total no. of mice
" Mice were orally treated with 50 mg of alkaloid kg-1 day-1 in 4-day test 
b Values are mean levels of parasitemia (95% confidence intervals). 
c Probability level of difference with control values. 
d Significantly different from controls in one-way ANOVA.
0/6
0 /6
0/6
0 /6
0 /6
0 /6
Day 7
% Parasitemia P
3.18 (0.00-6.82) 
0 .000  (0 .0 0 0 -0 .0 0 0 ) 
0.68 (0.00-1.35)
<o.ooid
0.008d
1.22 (1.02-1.41) 
0.53 (0.20-0.86) 
0.50 (0.36-0.64)
0 .00  l d 
<0.0001d
No. of dead mice/ 
total no. of mice
3/6
0 /6
0/6
0/6
0/6
0/6
There is a good correlation between the suppression of par­
asitemia of P. berghei Anka-infected OFl mice and the dose of 
dioncophylline C administered in the 4-day test (Table 3). The 
4-day schedule used for dioncophylline C is comparable to the 
chloroquine treatment scheme required to cure P. berghei 
Anka-infected O Fl mice (data not shown). A  minimum num-
C kg ”1 day- 1 was needed to cure all P. berghei-infected OFl 
mice (Table 4). It is encouraging (Table 4 and data not shown) 
that one oral treatment reduced the level of parasitemia by 
99.6% and produced 50% smear-negative mice at day 4.
The effects of dioncophylline C depend on the pharmacoki­
netic properties and bioavailability of the compound in the 
bloodstream. The difference in efficacy between the oral and 
subcutaneous route on the one hand and the intravenous route 
on the other hand could relate to chemical instability, limited 
absorption, a rapid metabolization in the gastrointestinal tract 
after oral administration, or the appearance of peak levels 
after intravenous application.
The strong effects of dioncophylline C administered to OFl 
mice starting 3 days after the infection (Table 5) suggest that 
less than five daily treatments could be considered sufficient to 
cure mice with established malaria infections. The somewhat 
lower activities of both dioncophylline C and dioncopeltine A
against the chloroquine-resistant P. berghei Anka CRS strain 
(Table 6) could possibly be improved in adapted administra­
tion schemes as well.
The most effective treatments with dioncophylline C and 
dioncopeltine A were obtained with subcutaneously implanted 
osmotic pumps, which allowed for the sustained release of the 
drugs at a rate of 1 |xl/h (Table 7). The high efficacy obtained 
with osmotic pumps suggests the importance of these and 
other sustained-release systems for the delivery of naphth­
ylisoquinoline alkaloids in future experiments and applica­
tions.
The considerable potential of the naphthylisoquinoline al­
kaloids as new antimalarial drugs, already strongly suggested 
by data obtained previously from in vitro experiments with 
P. falciparum and P. berghei (20, 22, 23), was confirmed by 
these results. Dioncophyllines B and C and dioncopeltine A  
are highly active against the rodent malaria parasite P. berghei 
in vivo, and in particular, dioncophylline C is a promising 
candidate for further development in the preclinical and clin­
ical phases. On the other hand, many more naphthylisoquino­
line alkaloids of natural and synthetic origin are waiting for 
further evaluation in the in vitro and in vivo malaria models. 
These new tools for the chemotherapy of malaria are badly 
needed, considering the deteriorating global malaria situation,
TABLE 7. Inhibitory effects of 20 mg of dioncophylline C and dioncopeltine A kg 1 day 1 on the course of parasitemia
of P. berghei K173-infected C57Black/6J mice applied with the aid of mini-osmotic pumps'1
Time after 
infection (day)
4
5
6
7
8 
14 
18 
21 
28
Mouse 1
1 
2  
13 
6 
12 
25 
50
t  
t
% Parasitemia*
Control Dioncophylline C
Mouse 2
5
10 
26 
27 
18
t 
t 
t  
t
Mouse 3
5 
9
14 
33
t 
t 
t 
f  
t
Mouse 1
0 
0 
0 
0 
0 
0C 
0 
0 
0
Mouse 2 
0
0
0
0
0'
0
0
0
Mouse 3 
0
0
0
0
0C
0
0
0
Dioncopeltine A
Mouse 1 Mouse 2 Mouse 3
0 0 0
0 « 1 « 1
« 1 0 « 1
0 0 0
0 0 0
0C 0C 0C
0 0 0
0 0 0
0 0 0
" Mice were infected intraperitoneally with 106 parasites at day 0. Osmotic pumps contained 16.6 mg of alkaloid/ml, released at 1 |xl/h, and were implanted
1 1 1 / /  V * _ _ J J_ 1subcutaneously in C57Black/6J mice at day -1 .
h Individual values for each mouse (t, dead). 
c No parasites present after isodiagnosis with samples from these mice with Swiss mice and observation for 4 weeks.
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the lack of commercially available vaccines, and the continuing 
spread of drug resistance.
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